{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T16:26:34Z","timestamp":1791822394451,"version":"4.3.4"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Prostate cancer (PCa) is the second most common malignant tumor in men worldwide, and its metastatic and heterogeneous nature makes it significantly more difficult to treat. Recent studies have revealed the critical role of microbiota in PCa occurrence, progression, and treatment. Accumulating evidence from 16S rRNA and metagenomic sequencing suggests the presence of specific microbiota in prostate tissues and macrogenomics techniques: cancerous tissues are enriched with pro-inflammatory genera (e.g., <jats:italic>Fusobacterium<\/jats:italic>, <jats:italic>Propionibacterium acnes<\/jats:italic>), whereas commensal bacteria (e.g., <jats:italic>Pseudomonas<\/jats:italic>) are more common in paracancerous tissues. The microbiota drive tumor progression through activation of the NF-\u03baB\/STAT3 pathway to induce chronic inflammation, modulation of the immune microenvironment (e.g., Treg\/Th17 imbalance and M2-type macrophage polarization), and metabolite (e.g., LPS, short-chain fatty acids)\u2013mediated hormonal and epigenetic regulation. In terms of clinical translation, urinary microbiota characterization combined with metabolomics analysis may enhance diagnostic specificity, while gut flora modulation (e.g., probiotic interventions or fecal transplants) may improve resistance to androgen deprivation therapy. Current challenges include sequencing accuracy of low-biomass samples, limitations of causal mechanism validation models, and large cohort heterogeneity. In the future, it will be necessary to integrate multi-omics technologies to explore the bidirectional regulation of the \u201cgut-prostate axis\u201d and develop personalized therapeutic strategies targeting microorganisms. In this paper, we systematically review the interactions between microbiota and PCa and their clinical potentials to provide a theoretical basis for precision diagnosis and treatment.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1576679","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T05:18:17Z","timestamp":1744607897000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Advances in human microbiome and prostate cancer research"],"prefix":"10.3389","volume":"16","author":[{"given":"Xin","family":"Pei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J clinicians"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.805459","article-title":"Prostate microbiota and prostate cancer: A new trend in treatment","volume":"11","author":"Che","year":"2021","journal-title":"Front Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12864-019-5457-z","article-title":"Metagenomic and metatranscriptomic analysis of human prostate microbiota from patients with prostate cancer","volume":"20","author":"Feng","year":"2019","journal-title":"BMC Genomics"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2022.862338","article-title":"Choice of 16S ribosomal RNA primers impacts male urinary microbiota profiling","volume":"12","author":"Heidrich","year":"2022","journal-title":"Front Cell infection Microbiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s13027-020-00319-2","article-title":"The human microbiome and its link in prostate cancer risk and pathogenesis","volume":"15","author":"Katongole","year":"2020","journal-title":"Infect Agents Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24021511","article-title":"Microbiome and prostate cancer: a novel target for prevention and treatment","volume":"24","author":"Kustrimovic","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/Cancers15051423","article-title":"Microbiota of urine, glans and prostate biopsies in patients with prostate cancer reveals a dysbiosis in the genitourinary system","volume":"15","author":"Gon\u00e7alves","year":"2023","journal-title":"cancers"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11040459","article-title":"The human microbiota and prostate cancer: friend or foe","volume":"11","author":"Massari","year":"2019","journal-title":"Cancers"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/nu12092648","article-title":"The crosstalk between prostate cancer and microbiota inflammation: are nutraceutical products useful to balance this interplay","volume":"12","author":"Crocetto","year":"2020","journal-title":"Nutrients"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23179664","article-title":"The oncobiome in gastroenteric and genitourinary cancers","volume":"23","author":"D\u2019Antonio","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1186\/s40168-022-01289-w","article-title":"Gut dysbiosis promotes prostate cancer progression and docetaxel resistance via activating NF-\u03baB-IL6-STAT3 axis","volume":"10","author":"Zhong","year":"2022","journal-title":"Microbiome"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00178","article-title":"Microbiome and cancers, with focus on genitourinary tumors","volume":"9","author":"Cimadamore","year":"2019","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.prnil.2022.10.001","article-title":"Possibilities and limitations of using low biomass samples for urologic disease and microbiome research","volume":"10","author":"Kim","year":"2022","journal-title":"Prostate Int"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2024.2313410","article-title":"Microbiome analysis reveals the inducing effect of Pseudomonas on prostatic hyperplasia via activating NF-\u03baB signalling","volume":"15","author":"Li","year":"2024","journal-title":"Virulence"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3390\/ph17010112","article-title":"Microbiome and prostate cancer: emerging diagnostic and therapeutic opportunities","volume":"17","author":"Kim","year":"2024","journal-title":"Pharmaceuticals"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2024.1431088","article-title":"Gut microbiome: a novel preventive and therapeutic target for prostatic disease","volume":"14","author":"Cao","year":"2024","journal-title":"Front Cell infection Microbiol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081549","article-title":"Prostate tissue microbiome in patients with prostate cancer: a systematic review","volume":"16","author":"Ward Grados","year":"2024","journal-title":"Cancers"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10204772","article-title":"The role of microbial factors in prostate cancer development-an up-to-date review","volume":"10","author":"Garbas","year":"2021","journal-title":"J Clin Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15092539","article-title":"Insights into the human microbiome and its connections with prostate cancer","volume":"15","author":"Munteanu","year":"2023","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.55145\/ajbms.2024.03.01.008","article-title":"Revealing the Urinary Microbiota in Prostate Cancer: a Comprehensive Review Unveiling Insights into Pathogenesis and Clinical Application. al-Salam","volume":"3","author":"Alajeeli","year":"2024","journal-title":"J Med Sci"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3969\/j.issn.1005-8982.2024.08.007","article-title":"Progress of urine metabolomics in prostate cancer","volume":"34","author":"Li","year":"2024","journal-title":"Chin J Modern Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1673-4416.2012.03.017","article-title":"Progress of urinary biomarkers in the diagnosis of prostate cancer","volume":"32","author":"Lai","year":"2012","journal-title":"Int J Urol"},{"key":"B23","first-page":"2012","volume-title":"Application of metabolomics to determine the prognosis of Chinese prostate cancer patients receiving endocrine therapy","author":"Huang","year":"2012"},{"key":"B24","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s12885-024-12018-x","article-title":"Gut microbiota in patients with prostate cancer: a systematic review and meta-analysis","volume":"24","author":"Huang","year":"2024","journal-title":"BMC Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1008353","article-title":"The gut mycobiome: The overlooked constituent of clinical outcomes and treatment complications in patients with cancer and other immunosuppressive conditions","volume":"16","author":"Galloway-Pe\u00f1a","year":"2020","journal-title":"PLoS Pathog"},{"key":"B26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13046-021-02196-y","article-title":"Dysbiotic microbes and how to find them: a review of microbiome profiling in prostate cancer","volume":"41","author":"Salachan","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2021-326264","article-title":"Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes","volume":"71","author":"Ting","year":"2022","journal-title":"Gut"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R116.765388","article-title":"Targeting of microbe-derived metabolites to improve human health: The next frontier for drug discovery","volume":"292","author":"Brown","year":"2017","journal-title":"J Biol Chem"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/nature11553","article-title":"Genomic approaches to studying the human microbiota","volume":"489","author":"Weinstock","year":"2012","journal-title":"nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1055\/s-0042-1760678","article-title":"A brief history of microbial study and techniques for exploring the gastrointestinal microbiome","volume":"36","author":"Sidebottom","year":"2023","journal-title":"Clinics colon rectal Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2020.10.013","article-title":"Deciphering organoids: high-dimensional analysis of biomimetic cultures","volume":"39","author":"Qin","year":"2021","journal-title":"Trends Biotechnol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s40168-019-0767-6","article-title":"Advancing functional and translational microbiome research using meta-omics approaches","volume":"7","author":"Zhang","year":"2019","journal-title":"Microbiome"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/biology13100762","article-title":"Contemporary update on clinical and experimental prostate cancer biomarkers: a multi-omics-focused approach to detection and risk stratification","volume":"13","author":"Hachem","year":"2024","journal-title":"Biology"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23095213","article-title":"Challenges in metabolomics-based tests, biomarkers revealed by metabolomic analysis, and the promise of the application of metabolomics in precision medicine","volume":"23","author":"Di Minno","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12010221","article-title":"Microbiota implications in endocrine -related diseases: from development to novel therapeutic approaches","volume":"12","author":"Clemente-Su\u00e1rez","year":"2024","journal-title":"Biomedicines"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.685935","article-title":"Key technologies for progressing discovery of microbiome-based medicines","volume":"12","author":"Young","year":"2021","journal-title":"Front Microbiol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1007\/s00253-018-9209-9","article-title":"Conducting metagenomic studies in microbiology and clinical research","volume":"102","author":"Martin","year":"2018","journal-title":"Appl Microbiol Biotechnol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11071800","article-title":"Intelligent biological networks: improving anti-microbial resistance resilience through nutritional interventions to understand protozoal gut infections","volume":"11","author":"Karpe","year":"2023","journal-title":"Microorganisms"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0142102","article-title":"COGNIZER: A framework for functional annotation of metagenomic datasets","volume":"10","author":"Bose","year":"2015","journal-title":"PLoS One"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1576679\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T15:47:23Z","timestamp":1749484043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1576679\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":39,"alternative-id":["10.3389\/fimmu.2025.1576679"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1576679","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"article-number":"1576679"}}